CAR T-cell therapy for neuroblastoma that has not responded
Part of Brain & nervous system, Cancer, Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests a new type of immune therapy (CAR T-cells) that is engineered to find and attack neuroblastoma cells by targeting specific markers (GD2, PSMA, and CD276) on the cancer cells. It is for patients whose cancer has not responded to standard treatments and who are healthy enough to receive this experimental cell therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have neuroblastoma that has not been cured by standard treatment, come back, or spread.
- Your tumor cells express at least one of the markers GD2, PSMA, or CD276 (which are found on many neuroblastoma cells).
- You weigh at least 22 pounds (10 kg) and are between 1 and 65 years old.
- Your vital organs (heart, lungs, liver, kidneys) are functioning reasonably well, and you are expected to live at least 8 more weeks.
- You have not had CAR T-cell therapy targeting GD2, PSMA, or CD276 before.
- You are able to stop taking steroids or immune-suppressing drugs, and you do not have an untreated infection or brain metastasis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special immune cell treatment (GD2-CAR T cells) for children and teens with neuroblastoma that has come back or not responded to standard therapy. It aims to see if these engineered cells can find and attack the cancer.
This Phase 1 study tests an experimental CAR T-cell treatment that targets GD2, with added immune-boosting and safety features, for children with relapsed or refractory neuroblastoma or osteosarcoma. It’s designed to see if the treatment is safe and can shrink these cancers when standard therapy hasn’t worked.
This trial tests a new treatment combining your child's own immune cells (NK cells) with an antibody that targets neuroblastoma cells. It is for children who have just finished standard treatment or whose cancer has come back or not responded, and aims to improve outcomes.
This trial tests a new type of immune cell therapy called CAR T cells that are designed to recognize and attack cancer cells in children and young adults with certain solid tumors that have come back or not responded to standard treatment.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
This trial tests a new immune therapy using your own cells (called B7-H3 CAR T cells) to treat solid tumors that haven't responded to other treatments. It may help children and young adults with certain cancers that are hard to cure.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.